KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Debt (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Total Debt for 7 consecutive years, with $121.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Debt changed N/A year-over-year to $121.3 million, compared with a TTM value of $121.3 million through Sep 2025, changed N/A, and an annual FY2024 reading of $93.8 million, changed N/A over the prior year.
  • Total Debt was $121.3 million for Q3 2025 at Alnylam Pharmaceuticals, roughly flat from $120.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $675.7 million in Q4 2021 and bottomed at $93.8 million in Q4 2024.
  • Average Total Debt over 3 years is $225.9 million, with a median of $120.8 million recorded in 2025.
  • Peak annual rise in Total Debt hit 253.25% in 2021, while the deepest fall reached 253.25% in 2021.
  • Year by year, Total Debt stood at $675.7 million in 2021, then plummeted by 86.12% to $93.8 million in 2024, then rose by 29.27% to $121.3 million in 2025.
  • Business Quant data shows Total Debt for ALNY at $121.3 million in Q3 2025, $120.8 million in Q2 2025, and $118.1 million in Q1 2025.